P
LGND icon

Pitcairn’s Ligand Pharmaceuticals LGND Stock Holding History

Pitcairn’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-6,085
Closed -$362K – 583
2020
Q3 		$362K Sell
6,085
-893
-13% -$60.9K 0.03% 318
2020
Q2 		$487K Buy
6,978
+223
+3% +$14.1K 0.05% 234
2020
Q1 		$307K Buy
6,755
+2,938
+77% +$167K 0.04% 294
2019
Q4 		$249K Sell
3,817
-255
-6% -$17K 0.02% 459
2019
Q3 		$252K Buy
4,072
+638
+19% +$40.1K 0.02% 452
2019
Q2 		$245K Sell
3,434
-27
-0.8% -$1.99K 0.02% 472
2019
Q1 		$272K Buy
3,461
+915
+36% +$69.3K 0.03% 389
2018
Q4 		$215K Sell
2,546
-593
-19% -$63.2K 0.02% 399
2018
Q3 		$537K Sell
3,139
-226
-7% -$34.1K 0.06% 234
2018
Q2 		$435K Sell
3,365
-617
-15% -$68.8K 0.05% 281
2018
Q1 		$410K Buy
3,982
+1,138
+40% +$113K 0.04% 283
2017
Q4 		$243K Sell
2,844
-93
-3% -$8.06K 0.02% 436
2017
Q3 		$250K Sell
2,937
-123
-4% -$9.74K 0.03% 405
2017
Q2 		$232K Sell
3,060
-127
-4% -$8.88K 0.03% 405
2017
Q1 		$210K Sell
3,187
-85
-3% -$5.59K 0.03% 460
2016
Q4 		$207K Sell
3,272
-370
-10% -$23.3K 0.03% 481
2016
Q3 		$232K Buy
3,642
+2
+0.1% +$147 0.03% 438
2016
Q2 		$271K Sell
3,640
-161
-4% -$11.9K 0.03% 364
2016
Q1 		$254K Buy
3,801
+696
+22% +$42.3K 0.03% 385
2015
Q4 		$210K Sell
3,105
-640
-17% -$39.5K 0.02% 408
2015
Q3 		$200K Sell
3,745
-314
-8% -$19.1K 0.03% 391
2015
Q2 		$256K Sell
4,059
-739
-15% -$40.3K 0.03% 398
2015
Q1 		$231K Buy
+4,798
New +$184K 0.03% 432

Other funds holding LGND

William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Pitcairn's LGND Position: Q4 2020 in Review

Pitcairn sold out of Ligand Pharmaceuticals (LGND) in Q4 2020, closing a stake of 6,085 shares — an estimated $362K sold.

Pitcairn first reported a position in LGND in Q1 2015 and held it in 23 quarters. The position peaked at $537K in Q3 2018. 242 funds tracked by Wall St. Rank hold LGND as of Q4 2020.

  • Pitcairn reported no remaining Ligand Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Pitcairn sold 6,085 Ligand Pharmaceuticals shares in Q4 2020, an estimated $362K.
  • Pitcairn first reported a position in Ligand Pharmaceuticals in Q1 2015 and held it in 23 quarters.
  • Pitcairn's Ligand Pharmaceuticals position peaked at $537K in Q3 2018.
  • 242 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2020.

Based on Pitcairn's 13F filing for Q4 2020, filed 5 Feb 2021.